Nama Insights

City Therapeutics (CTY)

Healthcare · Biotechnology · NASDAQ

City Therapeutics (CTY) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.03B and a free-cash-flow yield of -6.9%. Over the most recent reported fiscal year, revenue grew 388.2%.
Market cap$1.03B
Trailing P/E—
Price / book—
Price / sales69.0
FCF yield-6.9%
Dividend yield—
Gross margin0.0%
Operating margin-588.9%
Net margin0.0%
Revenue growth (YoY)+388.2%
Revenue growth (3-yr annual)—
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta—
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

CTY analyst price target

Median target $34.00 from 3 analysts, ranging $32.00 – $46.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $130.58B 27.1
REGN Regeneron Pharmaceuticals $95.24B 16.7
MRNA Moderna $78.90B —
ARGX argenx $58.21B 32.3
ONC BeOne Medicines $44.66B 49.7
RPRX Royalty Pharma $39.36B 12.9
RVMD Revolution Medicines $34.87B —
GMAB Genmab A/S $31.20B 36.7
Explore live CTY data on Nama Insights →

CTY FAQ

What is the CTY price target?
The median analyst price target from 3 analysts is $34.00, with a range of $32.00 – $46.00.